AbbVie Inc.

🇺🇸New York Stock Exchange
Back to all articles
AbbVie Inc. stock analysis ABBV overview
Bullish +75

Here are Thursday's biggest analyst calls: Nvidia, Amazon, Microsoft, Meta, Alphabet, Palantir, AbbVie & more

📈 Raymond James upgrades Equinix (EQIX) from outperform to strong buy following Q1 2026 results and AI-based demand.

💧 Deutsche Bank upgrades SiteOne Landscape to buy, citing a low valuation that implies 32% upside from their $160 price target.

🛡️ Roth Capital initiates coverage on Mistras with a buy rating and $22 price target due to improved operating efficiency.

🤖 Bank of America reiterates Nvidia (NVDA) as a buy, maintaining a $300 price target based on 28x CY27E PE.

💻 Oppenheimer initiates coverage of Palantir (PLTR) with an outperform rating and $200 price target.

📊 Baird upgrades Blackbaud to outperform from neutral after a solid Q1 beat and steady customer retention.

🔌 JPMorgan upgrades Teradyne to overweight following a stock pullback driven by lumpiness in customer purchasing.

⚠️ JPMorgan downgrades Meta (META) from overweight to neutral due to intensifying full-stack AI competition.

🌾 Bank of America upgrades Nutrien to buy, viewing the agriculture market as increasingly bullish.

💊 Bank of America upgrades AbbVie (ABBV) to buy from neutral, dismissing competition fears and citing strong immunology brand growth.

☁️ Morgan Stanley reiterates Microsoft as overweight, praising agentic computing expansion and AI-driven margin improvements.

🛒 Bank of America raises its Amazon price target to $310 from $298 following earnings on strong eCommerce and cloud assets.

🔍 JPMorgan raises Alphabet's price target to $460 from $395, citing clear returns on AI investments and doubled cloud backlog.

📰 Wells Fargo reiterates Meta as overweight, noting robust ad growth despite macro headwinds in the Middle East.

📱 Qualcomm receives a neutral hold from JPMorgan due to Q2 earnings beat but weak Q3 guidance influenced by smartphone headwinds.

Bullish Signals
  • Bank of America upgrades AbbVie to a Buy from Neutral, signaling confidence that competition fears are overdone.
  • Analysts at Bank of America rate ABBV as having a premium multiple well warranted given growth near the top of the peer group.
  • The firm sees strong and durable growth prospects in core immunology brands despite increasing competition.
  • There is significant upside potential tied to AbbVie's robust pipeline efforts according to Bank of America.
  • Bank of America identifies limited identifiable portfolio headwinds in the next 7 years for the stock.
Risk Factors
  • JPMorgan downgraded Meta from overweight to neutral due to rising competition and concerns that a full-stack AI intensifies pressure, making it harder for Meta to generate returns on heavy AI capital expenditures.
  • Wells Fargo noted that product catalysts for Meta seem pushed to the second half of the year, delaying the path to aggressive growth while operating expense ramp-up continues.
  • JPMorgan raised concerns about Qualcomm facing headwinds in the smartphone industry that drove its third-quarter guidance to track below consensus, partly due to expectations of another quarter of under-shipping relative to end customers.
  • The outlook for Meta includes macro headwinds related to the Middle East conflict impacting ad growth, with product catalysts delayed until later in the year.
Full Analysis
Bank of America upgraded AbbVie (ABBV) to a Buy rating from Neutral on Thursday, April 30, driven by the belief that fears regarding competition are overdone and that the company's premium valuation is warranted by its growth profile and durable pipeline. Analysts at the firm cited three primary reasons for the upgrade: ABBV's multiple looks justified given its top-tier growth relative to peers with limited identifiable headwinds in the next seven years; strong and durable growth prospects in its core immunology brands despite increasing competition; and significant upside potential tied to recent pipeline efforts. This move highlights a shift from defensive positioning toward a more bullish view on the biotech giant's long-term value proposition. The upgrade contrasts with other analyst activity on the day, such as JPMorgan downgrading Meta due to intensifying AI competition concerns, though Wells Fargo maintained an overweight rating on the same company citing robust ad growth and potential for future catalysts. While the broader market saw mixed signals across technology, including Bank of America raising its price target for Amazon and JPMorgan upgrading Teradyne, the specific focus on AbbVie in this analyst roundup underscores confidence in its pharmaceutical portfolio against competitors like Regeneron and potentially emerging biologic rivals. The upgrade implies that investors should view ABBV's growth trajectory as sustainable beyond immediate market pressures, particularly in its top-selling immunology drugs like Humira biosimilars where it maintains a lead through patent extensions or new formulations. The article itself aggregates these analyst calls from major financial institutions including Raymond James, Deutsche Bank, and Morgan Stanley, covering a wide range of sectors from semiconductor stocks like Nvidia and Qualcomm to cloud computing leaders such as Microsoft and Google. While AbbVie is one of many companies discussed in this Thursday briefing, the Bank of America upgrade serves as a notable positive development for the stock, suggesting that Wall Street is beginning to discount competition risks more favorably than previously priced in during the second quarter of fiscal year 2026.